Overview

Full Product Details

Author:   Daniel Bar-Shalom ,  Klaus Rose
Publisher:   Springer-Verlag New York Inc.
Imprint:   Springer-Verlag New York Inc.
Edition:   Softcover reprint of the original 1st ed. 2014
Volume:   11
Dimensions:   Width: 15.50cm , Height: 2.30cm , Length: 23.50cm
Weight:   6.847kg
ISBN:  

9781493945214

ISBN 10:   1493945211
Pages:   439
Publication Date:   23 August 2016
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   Manufactured on demand  
We will order this item for you from a manufactured on demand supplier.

Table of Contents

Pediatric Development: Anatomy.- Age, Weight, Body Surface and Stature, Organ Development.- Pediatric Development: Physiology. Enzymes, Drug Metabolism, Pharmacokinetics and Pharmacodynamics.- Pediatric Development – Gastrointestinal.- How to Estimate the Dose to be Given for the First Time to Pediatric Patients.- The Clinical Relevance of Pediatric Formulations.- General Considerations for Pediatric Oral Drug Formulation.- Orosensory Perception.- Flavor Is Not Just Taste: Taste Concealing.- Liquid Formulations.- Paediatric Solid Formulations.- Semi-Solid Formulations.- The Challenge of Automated Compounding.- Pediatric Formulations in Clinical Testing and the Challenge of Final Market Formulation.- Buccal/Sublingual Drug Delivery for the Paediatric Population.- Topical and Transdermal.- Parenteral Liquids for Intravenous and Transdermal Use.- The Challenges of Paediatric Pulmonary Drug Delivery.- Nasal, Ocular and Otic Drug Delivery.- Rectal Drug Delivery.- Intraosseous Infusions in Infants and Neonates.- Compounding for Children – The Compounding Pharmacist.- Food Ingredients.- Excipients and Active Pharmaceutical Ingredients (APIs).- Clinical Testing in Children.- Pediatric Formulations and Dosage Forms and Future Opportunities: Impact of Regulations in the United States and Implementation of Quality by Design.- Pediatric Pharmaceutical Legislation and its impact on Adult and Pediatric Drug Development: The EU Regulatory View.- Pediatric Pharmaceutical Legislation in USA and EU and their impact on Adult and Pediatric Drug Development.- Checks and Balances in the EU: The Role of the European Ombudsman, with a Focus on the Paediatric Regulation.- The Dangerous Business Of Predicting The Future.

Reviews

From the reviews: “This book can be useful not only for those in drug development, but also for pharmacists who work in pediatrics (either hospital or community pharmacists), compounding pharmacists, pediatricians, nurses who specialize in this area, and certainly students or residents in any of these disciplines who plan to focus on pediatrics. … I have reviewed and used many books on drug formulations and pharmaceutics, but I have not seen such a complete book devoted specifically to pediatrics.” (Patrick J. McDonnell, Doody’s Book Reviews, July, 2014)

From the reviews: This book can be useful not only for those in drug development, but also for pharmacists who work in pediatrics (either hospital or community pharmacists), compounding pharmacists, pediatricians, nurses who specialize in this area, and certainly students or residents in any of these disciplines who plan to focus on pediatrics. ... I have reviewed and used many books on drug formulations and pharmaceutics, but I have not seen such a complete book devoted specifically to pediatrics. (Patrick J. McDonnell, Doody's Book Reviews, July, 2014)

Author Information

Daniel Bar-Shalom is an Associate Professor in Drug Delivery at The Faculty of Health and Medical Sciences, University of Copenhagen. He has a degree in Biology from The Tel-Aviv University (1975), carried research in botany and then graduated from the School of Pharmacy, Hebrew University of Jerusalem (1982). He is a qualified pharmacist and has managed and owned a pharmacy in Haifa where he gained insight into the needs and idiosyncrasies of patients. He moved to Denmark in 1986 and founded Egalet, a drug delivery company where he served until 2007 as Vice President, R&D. He has been a consultant for various pharmaceutical and medical device companies. He is also the inventor of various technologies, holds many patents and has formulated marketed products. His main interests are controlled drug delivery and in particular oral pediatric formulations and geriatric formulations addressing the problem of polypharmacy. Dr. Klaus Rose is CEO of Klausrose Consulting, Switzerland and advises on pediatric drug development and how to comply with FDA and EMA pediatric requirements. He has studied Latin languages, psychology and medicine. After postgraduate clinical training in general medicine in Germany and England, he joined the pharmaceutical industry. He has held various positions in R&D and medical affairs, was Global Head Pediatrics Novartis from 2001 to 2005 and was Global Head Pediatrics Roche from 2005 to 2009. After a year with a regulatory consultancy, he established his own business. Dr. Rose is a frequent speaker on international conferences on pediatric drug development, organizes trainings and publishes on a regular base.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions